ETFs with exposure to Intrexon Corp.
Here are 5 ETFs with the largest exposure to XON-US. Comparing the performance and risk of Intrexon Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility.
|Ticker||Fund Name||XON-US Exposure (%)||1 Year Price Performance (%)||1 Year Volatility (%)||Net Expense Ratio (%)||Number of Holdings|
|FBT-US||First Trust NYSE Arca Biotechnology Index Fund||2.64||21.46||23.97||0.55||30|
|BTEC-US||Principal Healthcare Innovators Index ETF||0.89||18.8||26.12||0.42||143|
|XBI-US||SPDR S&P Biotech ETF||0.71||28.85||27.92||0.35||98|
|ARKG-US||ARK Genomic Revolution Multi-Sector ETF||0.48||32.19||26.83||0.75||39|
|SIZ-US||QuantShares U.S. Market Neutral Size Fund||0.44||-8.01||7.84||0.75||403|
Use our ETF screener to find ETFs that hold XON-US along with other stocks
ETFs with exposure to stocks in the same focus area as Intrexon Corp..
Here are 5 ETFs with the largest exposure to stocks in the same focus area and region as XON-US. These ETFs may not have the highest percentage of Intrexon Corp., but offer a broader sector/region exposure further minimizing single stock risk. Comparing the performance and risk of Intrexon Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility.
|Ticker||Fund Name||XON-US Exposure (%)||Sector Exposure (%)||1 Year Price Performance (%)||1 Year Volatility (%)||Net Expense Ratio (%)||Number of Holdings|
|IBB-US||iShares Nasdaq Biotechnology ETF||0||67.49||14.36||20.93||0.47||161|
|BBH-US||VanEck Vectors Biotech ETF||0||65.78||15.44||18.99||0.35||26|
|XBI-US||SPDR S&P Biotech ETF||0.71||62.15||28.85||27.92||0.35||98|
|FBT-US||First Trust NYSE Arca Biotechnology Index Fund||2.64||58.13||21.46||23.97||0.55||30|
|PBE-US||Powershares Dynamic Biotechnology & Genome Portfolio||0||55.08||17.49||23.4||0.59||31|
Use our natural language search to find ETFs in any focus area
The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any of our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.
*Disclaimer : This is as of previous day’s close